BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

602 related articles for article (PubMed ID: 18337732)

  • 1. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
    Lilja H; Ulmert D; Vickers AJ
    Nat Rev Cancer; 2008 Apr; 8(4):268-78. PubMed ID: 18337732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen kinetics in localized and advanced prostate cancer.
    Fitzpatrick JM; Banu E; Oudard S
    BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen in clinical practice.
    Loeb S; Catalona WJ
    Cancer Lett; 2007 Apr; 249(1):30-9. PubMed ID: 17258389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meanings of prostate-specific antigen testing as narrated by men with localized prostate cancer after primary treatment.
    Hedestig O; Sandman PO; Widmark A; Rasmussen BH
    Scand J Urol Nephrol; 2008; 42(2):101-9. PubMed ID: 17907052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indications and timing for prostate biopsy, diagnosis of early stage prostate cancer and its definitive treatment: a clinical conundrum in the PSA era.
    Punnen S; Nam RK
    Surg Oncol; 2009 Sep; 18(3):192-9. PubMed ID: 19282170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen testing for prostate cancer. Practical interpretation of values.
    Randrup E; Baum N
    Postgrad Med; 1996 Feb; 99(2):227-8, 231-4. PubMed ID: 8632969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
    BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prostatic specific antigen: role and significance in urologic practice].
    Manolović D; Pejcić T; Milović N
    Srp Arh Celok Lek; 1994; 122(5-6):171-3. PubMed ID: 17977420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Screening for prostate cancer: role of PSA in 2006].
    Roumeguère T; Peltier A
    Rev Med Brux; 2006 Sep; 27(4):S225-31. PubMed ID: 17091883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of prostate-specific antigen and prostate-specific antigen density in detection of prostate cancer in an Iranian population of men.
    Ghafoori M; Varedi P; Hosseini SJ; Asgari M; Shakiba M
    Urol J; 2009; 6(3):182-8. PubMed ID: 19711272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA?
    Connolly D; Black A; Murray LJ; Nambirajan T; Keane PF; Gavin A
    Prostate Cancer Prostatic Dis; 2009; 12(1):47-51. PubMed ID: 18762815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSA and other tissue kallikreins for prostate cancer detection.
    Stephan C; Jung K; Lein M; Diamandis EP
    Eur J Cancer; 2007 Sep; 43(13):1918-26. PubMed ID: 17689069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PSA-based screening for prostate cancer: how does it compare with other cancer screening tests?
    Crawford ED; Abrahamsson PA
    Eur Urol; 2008 Aug; 54(2):262-73. PubMed ID: 18556114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The detection rate of prostate cancer in different prostate-specific antigen (PSA) levels in Chinese men].
    Li M; Na YQ
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(1):16-8. PubMed ID: 18346372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostatic-specific antigen velocity after holmium laser enucleation of the prostate: possible predictor for the assessment of treatment effect durability for benign prostatic hyperplasia and detection of malignancy.
    Elmansy HM; Elzayat EA; Sampalis JS; Elhilali MM
    Urology; 2009 Nov; 74(5):1105-10. PubMed ID: 19773035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum markers for prostate cancer: a rational approach to the literature.
    Steuber T; O'Brien MF; Lilja H
    Eur Urol; 2008 Jul; 54(1):31-40. PubMed ID: 18243505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen.
    Fradet Y
    Curr Opin Urol; 2009 May; 19(3):243-6. PubMed ID: 19325493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
    Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
    Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis.
    Sarrats A; Comet J; Tabarés G; Ramírez M; Aleixandre RN; de Llorens R; Peracaula R
    Prostate; 2010 Jan; 70(1):1-9. PubMed ID: 19670261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychological distress and prostate specific antigen levels in men with and without prostate cancer.
    Turner EL; Lane JA; Metcalfe C; Down L; Donovan JL; Hamdy F; Neal D; Vedhara K
    Brain Behav Immun; 2009 Nov; 23(8):1073-8. PubMed ID: 19486654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.